FI
SYRE icon

Fosun International’s Spyre Therapeutics SYRE Stock Holding History

Fosun International’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-8,166
Closed -$1.31M – 288
2019
Q2 		$1.31M Buy
8,166
+1,120
+16% +$194K 0.09% 139
2019
Q1 		$1.4M Buy
7,046
+3,160
+81% +$659K 0.09% 129
2018
Q4 		$778K Buy
+3,886
New +$824K 0.05% 172

Other funds holding SYRE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fosun International's SYRE Position: Q3 2019 in Review

Fosun International sold out of Spyre Therapeutics (SYRE) in Q3 2019, closing a stake of 8,166 shares — an estimated $1.31M sold.

Fosun International first reported a position in SYRE in Q4 2018 and held it in 3 quarters. The position peaked at $1.4M in Q1 2019. 71 funds tracked by Wall St. Rank hold SYRE as of Q3 2019.

  • Fosun International reported no remaining Spyre Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Fosun International sold 8,166 Spyre Therapeutics shares in Q3 2019, an estimated $1.31M.
  • Fosun International first reported a position in Spyre Therapeutics in Q4 2018 and held it in 3 quarters.
  • Fosun International's Spyre Therapeutics position peaked at $1.4M in Q1 2019.
  • 71 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2019.

Based on Fosun International's 13F filing for Q3 2019, filed 12 Nov 2019.